ISTH 2022 Supported Symposia & Presentation Theaters
(as of 6/13/22)

​

The following companies will organize supported symposia and/or presentation theater sessions at the ISTH 2022 Congress in London, showcasing the latest scientific, diagnostic and therapeutic advances in thrombosis and hemostasis. 

​

See below for session titles.

​

Live Supported Symposia and Presentation Theaters

​​

Saturday, July 9, 11:30 – 12:45 Supported Symposia

• AAV Gene Therapies: Learnings From Clinical Trials to Inform Real World Discussions (BioMarin Pharmaceutical Inc.) 

• Anticoagulant Advancements for VTE in All Ages and NVAF in Adult Patients (Boehringer Ingelheim)

• Living with ITP: Thrombotic Risk and Patient’s Perspective (GRIFOLS)

• A Key Factor: Aiming for All-Round Bleed Protection in Haemophilia A (Octapharma AG)

• Shining a Light on Severe Congenital Protein C Deficiency (SCPCD) (Takeda Pharmaceutical Company Limited)

​

Sunday, July 10, 07:00 – 07:45 Supported Symposium

• Navigating the Joint Health Journey for Patients With Hemophilia: How Can You Make A Lasting Impact? (MedScape/ISTH/Takeda Pharmaceuticals U.S.A, Inc.)

​

Sunday, July 10, 12:15 – 13:00 Presentation Theaters

• Achieving Balance with Prophylaxis in Hereditary Factor X Deficiency – Treatment Across the Ages (Bio Products Laboratory Ltd.)

• MRX PT DOAC – a New Way to Measure the Effect of DOACs (Nordic Biomarker)

• Rapid Reversal of DOACs: Current and Future Perspectives (Norgine)

• Managing the Challenges of IVDR Transition Together (Siemens Healthineers)

​

Sunday, July 10, 13:15 – 14:30 Supported Symposia

• Make the Right Call: Protecting Vulnerable Patients With Venous Thrombosis (Bayer AG)

• Advancing Care for Haemophilia: How Do We Keep Up With the Times? (CSL Behring)

• Evidence-Based Responses to Key Clinical Questions Relating to Hemophilia A Management (F. Hoffmann-La Roche Ltd)

• COVID-19 Coagulopathy and Long COVID: Haemostatic Changes and Implications for Diagnosis and Treatment (Haemonetics Corporation)

• Health Equity for Haemophilia Patients with Inhibitors: Can We Do More? (LFB)

• Mind the Gap: The Journey to Address Unmet Needs Across all Haemophilia Indications (Novo Nordisk)

• Immune Thrombocytopenia: Disease Burden and Treatment Challenges in the COVID-19 Era (Sanofi)

​

Monday, July 11, 07:00 – 07:45 Supported Symposium

• Management of Thrombosis in High-Risk Patients: Focus on Cancer-Associated Thrombosis (CAT) (Anthos Therapeutics)

​

Monday, July 11, 07:00 – 07:45 Presentation Theater

• Implementing a Multimodal Approach to VTE Prevention Today (Cardinal Health)

​

Monday, July 11, 12:15 – 13:00 Presentation Theaters

• Advances in von Willebrand Disease (vWD): A View From the Clinic (CSL Behring)

• Driving Change: Improving Diagnosis of Heavy Menstrual Bleeding and Bleeding Disorders in Women and Girls (Novo Nordisk Healthcare AG)

• Lupus Anticoagulant Diagnostics: Why you Need More Snakes (Technoclone)

• ADAMTS13 and von Willebrand Factor Axis (Werfen)

​

Monday, July 11, 13:15 – 14:30 Presentation Theaters

• Roundtable Discussion: Clinical Challenges in Patients with Venous Thromboembolism – Following the Data (BMS/Pfizer)

• Improving Patient Care through Innovative Thrombosis and Haemostasis Testing. LumiraDx: Microfluidic Technology in POC Testing (LumiraDx)

• Approaches to Standardisation and Monitoring for Haemophilia Gene Therapy: Consistency, Considerations and Challenges (Pfizer)

• Improving Outcomes in Acute Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Can We Reduce Mortality? (Sanofi)

• Factors to Consider: Expert Perspectives on Haemophilia A (Sobi Sanofi)

• A Chronic Disease Burden: Exploring the Acute and Long-term Manifestations of TTP on Patients’ Lives (Takeda Pharmaceutical Company Limited)

 

Tuesday, July 12, 12:15 – 13:00 Presentation Theaters

• Breakthrough Applications for Thrombin Generation (Diagnostica Stago)

• Current Advances in Deficient Factors, D-Dimer and Thrombophilia Testing (HORIBA Medical)

• Insights From Real World Practice to Support Haemophilia B Patients (Sobi Sanofi)

• Building a Future in Haemostasis: A new-age in Laboratory Workflow and Automation with the Sysmex CN-Series (Sysmex)

​

Tuesday, July 12, 13:15 – 14:30 Supported Symposia

• Strategies for Assessing and Managing DOAC-Related Bleeding (AstraZeneca)

• Focus on Females: Patient Experience & Novel Treatment Strategies in Bleeding Disorders (Octapharma AG)

• Advances in Diagnosis and Management of Bleeding Disorders (Roche)

• Medically-Ill Patients: VTE Prophylaxis in Hospital and Beyond (Sanofi)

• Towards Health Equity: Upcoming Standards in Haemophilia Management (Sanofi)

• Immune Thrombocytopenia: A Numbers Game? (Sobi)

• Looking Towards the Future: Individualizing Treatment for Patients with Congenital and Acquired Hemophilia A (Takeda Pharmaceutical Company Limited)

​

For more information on these sessions, visit the online program here.